Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. Learn how you can help make a difference by joining the All of Us Research Program.
Displaying 31 - 40 of 265
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (TAILOR RT)
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)
Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with r/r MM
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
Olanzapine vs Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Cancer, Colorectal, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers, Breast Cancers, Brain and Spine Cancers, Other Respiratory, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Ovary, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus
To determine the safety and tolerability of CC-92328 in subjects with R/R MM. To define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-92328 in subjects with R/R MM.
A Phase 1 Study of Spyk04 as Monotherapy in Patients with Solid Tumors
Cancer, Ovary, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Breast Cancers, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus, Colorectal, Gynecologic Cancers
A Phase 1/2 FIH Study of ISB 1442 in Patients with R/R MM
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Renal Metabolism Study